DrugPatentWatch Database Preview

Lannett Co Inc Company Profile

LANNETT CO INC has one hundred and thirty-one approved drugs.

There is one US patent protecting LANNETT CO INC drugs.

There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and nine supplementary protection certificates in twelve countries.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	CODEINE SULFATE	codeine sulfate	TABLET;ORAL	203046-003	Jun 13, 2014	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Lannett Co Inc	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	205022-002	Sep 19, 2016	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Lannett Co Inc	NITROGLYCERIN	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	075115-002	Aug 10, 2004		DISCN	No	No		➤ Sign Up				➤ Sign Up
Lannett Co Inc	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	TABLET;ORAL	089743-003	Aug 25, 1988	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Lannett Co Inc	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	088894-001	Apr 11, 1985		DISCN	No	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lannett Co Inc	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Extended-release Capsules	40 mg	➤ Subscribe	2007-03-15
➤ Subscribe	Extended-release Capsules	10 mg, 20 mg and 30 mg	➤ Subscribe	2005-05-13

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003503	C01003503/01	Switzerland	➤ Sign Up	PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
0268956	SPC/GB98/040	United Kingdom	➤ Sign Up	PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
1304992	2013C/060	Belgium	➤ Sign Up	PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
1003503	SZ 30/2006	Austria	➤ Sign Up	PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
0392059	SPC/GB02/046	United Kingdom	➤ Sign Up	PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.